Trial Profile
A Study to Evaluate the Treatment Outcome and Development of New Mutations in Patients With Imatinib- and/or Nilotinib-Failure Philadelphia Chromosome Positive (Ph+) Leukemia With Highly Nilotinib Resistant Mutations Treated With Dasatinib
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 May 2016
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary)
- Indications Leukaemia
- Focus Pharmacodynamics; Therapeutic Use
- 23 May 2016 New trial record